Literature DB >> 18197514

Ketamine followed by memantine for the treatment of major depression.

Rainer Kollmar, Katrin Markovic, Norbert Thürauf, Hubert Schmitt, Johannes Kornhuber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18197514     DOI： 10.1080/00048670701787628

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN： 0004-8674            Impact factor:   5.744


× No keyword cloud information.
  10 in total

Review 1.  Ketamine for depression: where do we go from here?

Authors:  Marije Aan Het Rot; Carlos A Zarate; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2012-06-16       Impact factor: 13.382

Review 2.  Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Authors:  Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

Review 3.  Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.

Authors:  Mark J Niciu; Dawn F Ionescu; Erica M Richards; Carlos A Zarate
Journal:  J Neural Transm (Vienna)       Date:  2013-12-08       Impact factor: 3.575

Review 4.  The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence.

Authors:  Gabriele Sani; Giulia Serra; Giorgio D Kotzalidis; Silvia Romano; Stefano M Tamorri; Giovanni Manfredi; Matteo Caloro; C Ludovica Telesforo; Saverio S Caltagirone; Isabella Panaccione; Alessio Simonetti; Francesca Demontis; Gino Serra; Paolo Girardi
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 5.749

Review 5.  Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.

Authors:  Nicolas D Iadarola; Mark J Niciu; Erica M Richards; Jennifer L Vande Voort; Elizabeth D Ballard; Nancy B Lundin; Allison C Nugent; Rodrigo Machado-Vieira; Carlos A Zarate
Journal:  Ther Adv Chronic Dis       Date:  2015-05       Impact factor: 5.091

6.  Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.

Authors:  Sanjay J Mathew; James W Murrough; Marije aan het Rot; Katherine A Collins; David L Reich; Dennis S Charney
Journal:  Int J Neuropsychopharmacol       Date:  2009-03-17       Impact factor: 5.176

7.  Memantine: a review of possible uses in child and adolescent psychiatry.

Authors:  Sheik Hosenbocus; Raj Chahal
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2013-05

Review 8.  Memantine in neurological disorders - schizophrenia and depression.

Authors:  Kamila Czarnecka; Jakub Chuchmacz; Przemysław Wójtowicz; Paweł Szymański
Journal:  J Mol Med (Berl)       Date:  2021-01-14       Impact factor: 4.599

Review 9.  Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.

Authors:  Brittany A Jaso; Mark J Niciu; Nicolas D Iadarola; Niall Lally; Erica M Richards; Minkyung Park; Elizabeth D Ballard; Allison C Nugent; Rodrigo Machado-Vieira; Carlos A Zarate
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

10.  A research study review of effectiveness of treatments for psychiatric conditions common to end-stage cancer patients: needs assessment for future research and an impassioned plea.

Authors:  Ralph J Johnson
Journal:  BMC Psychiatry       Date:  2018-04-03       Impact factor: 3.630
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.